Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by Fisher Asset Management LLC

Fisher Asset Management LLC grew its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 9.4% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 5,635 shares of the biopharmaceutical company’s stock after buying an additional 485 shares during the quarter. Fisher Asset Management LLC’s holdings in Regeneron Pharmaceuticals were worth $4,949,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. FMR LLC lifted its stake in Regeneron Pharmaceuticals by 7.3% in the 3rd quarter. FMR LLC now owns 9,840,892 shares of the biopharmaceutical company’s stock worth $8,098,661,000 after purchasing an additional 669,517 shares in the last quarter. Northern Trust Corp lifted its position in Regeneron Pharmaceuticals by 3.3% during the third quarter. Northern Trust Corp now owns 1,067,210 shares of the biopharmaceutical company’s stock worth $878,271,000 after buying an additional 34,326 shares in the last quarter. Morgan Stanley boosted its stake in Regeneron Pharmaceuticals by 2.7% during the third quarter. Morgan Stanley now owns 970,957 shares of the biopharmaceutical company’s stock worth $799,061,000 after buying an additional 25,792 shares during the last quarter. American Century Companies Inc. grew its holdings in Regeneron Pharmaceuticals by 3.4% in the 3rd quarter. American Century Companies Inc. now owns 916,718 shares of the biopharmaceutical company’s stock valued at $754,422,000 after buying an additional 30,050 shares in the last quarter. Finally, International Assets Investment Management LLC increased its stake in shares of Regeneron Pharmaceuticals by 76,169.5% in the 4th quarter. International Assets Investment Management LLC now owns 591,089 shares of the biopharmaceutical company’s stock worth $519,148,000 after acquiring an additional 590,314 shares during the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

REGN has been the topic of several recent research reports. Truist Financial reissued a “buy” rating and set a $1,135.00 price target on shares of Regeneron Pharmaceuticals in a research report on Wednesday, April 3rd. TD Cowen increased their price target on shares of Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the company a “buy” rating in a research note on Wednesday, April 24th. StockNews.com downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, April 30th. BMO Capital Markets upped their price objective on Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the company an “outperform” rating in a report on Monday, February 5th. Finally, Bank of America raised their target price on Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the stock an “underperform” rating in a research note on Friday, April 12th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have assigned a buy rating to the stock. According to MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $981.71.

Insider Activity

In related news, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction on Friday, March 1st. The stock was sold at an average price of $982.05, for a total transaction of $98,205.00. Following the completion of the transaction, the director now directly owns 18,282 shares of the company’s stock, valued at approximately $17,953,838.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $982.05, for a total value of $98,205.00. Following the completion of the transaction, the director now owns 18,282 shares in the company, valued at $17,953,838.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Andrew J. Murphy sold 5,783 shares of the business’s stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the transaction, the executive vice president now owns 48,306 shares of the company’s stock, valued at approximately $46,203,239.82. The disclosure for this sale can be found here. Over the last three months, insiders have sold 8,095 shares of company stock worth $7,779,766. Corporate insiders own 8.83% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $969.97 on Wednesday. The firm has a 50 day moving average of $942.67 and a two-hundred day moving average of $899.44. The stock has a market capitalization of $106.47 billion, a PE ratio of 28.65, a P/E/G ratio of 2.74 and a beta of 0.17. The company has a quick ratio of 4.51, a current ratio of 5.27 and a debt-to-equity ratio of 0.10. Regeneron Pharmaceuticals, Inc. has a 52 week low of $684.80 and a 52 week high of $998.33.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.